Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài:Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - nonscleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining. | Ceribelli et al. Arthritis Research Therapy 2011 13 R119 http arthritis-research.eom content 13 4 R119 RESEARCH ARTICLE Open Access Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - nonscleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining 1 2 2 1.2 2 1 Angela Ceribelli Malgorzata E Krzyszczak Yi Li Steven J Ross 1 Jason YF Chan Edward KL Chan D ifi IC A Ri lídinr-iamo3 Tx lor T A oHh3 Í Iir kì2í2il R R iHh2 Rrif R Rr ihol2 4 A ocflox I I Roox oc2 4 K linmi i I Ratmh2 4 Ruius W Burlingame 1 Tyler I Webb 1 Michael R DUbb 1 Eiic S Sobel 1 Westley H Reeves and Minoru satoii Abstract Introduction Anti-RNA polymerase III RNAP III antibodies are highly specific markers of scleroderma systemic sclerosis1 SSc and associated with a rapidly progressing subset of SSc. The clinical presentation of anti-RNAP III positive patients1 onset of Raynaud s phenomenon RP and SSc in unselected patients in a rheumatology clinic were evaluated. Methods Autoantibodies in sera from I1966 unselected patients including 434 systemic lupus erythematosus SLE 119 SSc 85 polymyositis dermatomyositis PM DM in a rheumatology clinic were screened by radioimmunoprecipitation. Anti-RNAP III positive sera were also tested by immunofluorescence antinuclear antibodies and anti-RNAP III ELISA. Medical records of anti-RNAP III positive patients were reviewed. Results Among 21 anti-RNAP III positive patients1 16 met the American College of Rheumatology ACR SSc criteria at the initial visit but 5 did not diagnoses were vasculitis early polyarthritis renal failure with RP interstitial lung disease1 and Sjogren s syndrome. The first two patients developed rapidly progressive diffuse SSc. An additional case presented with diffuse scleroderma without RP and RP developed two years later. Anti-RNAP III antibodies in these 6 cases of atypical clinical presentation were compared with those in 15 cases of typical SSc with RP cases. Anti-RNAP .
